US EditionPublished • loading... • Updated
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week
Summary by ts2.tech
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week
New York, January 28, 2026, 13:02 EST — Trading in regular session. Pfizer shares dropped 1.8% to $26.02 in early afternoon trading, having fluctuated between $25.97 and $26.39. The pullback arrives as investors absorb a fresh U.S. Medicare drug-pricing list featuring Pfizer’s arthritis drug Xeljanz. For major pharmaceutical companies, the inclusion signals that Washington’s price cuts have shifted from headline risk to a ticking clock on the ca…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
